Esperion Unveils Promising Research Supporting Lead Development Candidates for Primary Sclerosing Cholangitis (PSC) at R&D Day 2025

Stock Information for Esperion Therapeutics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Esperion Therapeutics Inc.

Esperion's Bempedoic Acid Receives Level 1a Recommendation in Updated ESC/EAS Guidelines for Management of Dyslipidaemias
Esperion to Participate in Upcoming September Investor Conferences
HLS Therapeutics Announces Q2 2025 Financial Results
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Esperion Reports Second Quarter 2025 Financial Results and Provides Business Update
Esperion to Report Second Quarter 2025 Financial Results on August 5
Esperion Reaches Settlement Agreement with Third ANDA Filer Not to Market Generic Version of NEXLETOL® (bempedoic acid) Prior to April 19, 2040
Esperion Appoints Craig Thompson to Board of Directors

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.